ORIC on Nasdaq

Oric Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by O vercoming R esistance I n C ancer.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerORIC on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersSan Francisco, United States2
  • Incorporated inDE3
  • Business address240 E. Grand Ave., 2Nd Floor, South San Francisco, Ca 940803
  • Filer categoryNon-accelerated filer3
  • Legal formCorporation2
  • LEI54930033FJRNEYBW0L252
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 55953822

See how the biggest companies compare on our leaderboards

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by O vercoming R esistance I n C ancer .4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income56789-$143.0M in 2025+401% since 2019
-$150.0M-$100.0M-$50.0M02019: -$28.6M-$28.6M20192020: -$74.2M-$74.2M2020+160%2021: -$78.9M-$78.9M2021+6%2022: -$91.8M-$91.8M2022+16%2023: -$110.8M-$110.8M2023+21%2024: -$142.9M-$142.9M2024+29%2025: -$143.0M-$143.0M2025+0%
Net income56789-$129.5M in 2025+382% since 2019
-$150.0M-$100.0M-$50.0M02019: -$26.9M-$26.9M20192020: -$73.7M-$73.7M2020+174%2021: -$78.7M-$78.7M2021+7%2022: -$89.1M-$89.1M2022+13%2023: -$100.7M-$100.7M2023+13%2024: -$127.8M-$127.8M2024+27%2025: -$129.5M-$129.5M2025+1%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development$109.8M$114.1M
General and administrative$33.2M$28.8M
Total operating expenses$143.0M$142.9M
Loss from operations-$143.0M-$142.9M
Other income, net$13.5M$15.0M
Net loss-$129.5M-$127.8M
Unrealized gain on investments$407.0K$121.0K
Comprehensive loss-$129.1M-$127.7M
Net loss per share, basic-$1.47-$1.83
Net loss per share, diluted-$1.47-$1.83
Weighted-average shares outstanding, basic87.8M shares69.7M shares
Weighted-average shares outstanding, diluted87.8M shares69.7M shares

Compare Oric Pharmaceuticals, Inc. with another company

Leadership

Who has led Oric Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jacob Chacko2020–now

President

  1. Jacob Chacko2020–now

Chief financial officer

  1. Dominic Piscitelli2020–now
2025
Board members and other officers (10)

Timeline

  1. Apr 23, 2020New chief executive Jacob Chacko becomes CEO13
  2. Aug 29, 2014Founded Oric Pharmaceuticals, Inc. is founded2

Filings

279 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 93 insider forms, 53 large holders, 3 private raises, 62 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Oct 1, 2026144 EDGAR
  3. Oct 1, 2026144 EDGAR
  4. Sep 29, 20264 EDGAR
  5. Sep 25, 20264 EDGAR
  6. Aug 28, 20264 EDGAR
  7. Aug 26, 2026144 EDGAR
  8. Aug 3, 202610-Q EDGAR
  9. Aug 3, 20268-K EDGAR
  10. Jul 30, 2026S-8 EDGAR
  11. Jul 30, 20268-K EDGAR
  12. Jul 28, 20264 EDGAR
  13. Jul 8, 20264 EDGAR
  14. Jul 6, 2026144 EDGAR
  15. Jul 6, 2026144 EDGAR
  16. Jun 22, 20268-K EDGAR
  17. May 15, 2026SCHEDULE 13G/A EDGAR
  18. May 15, 2026SCHEDULE 13G/A EDGAR
  19. May 15, 2026SCHEDULE 13G/A EDGAR
  20. May 15, 2026SCHEDULE 13G EDGAR

The 279 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

51 open-market trades by officers, directors and large owners since October 2021: 9 buys and 42 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 28, 2026Piscitelli DominicChief Financial OfficerSale13,400$13.53$181.3KForm 4
Sep 24, 2026Piscitelli DominicChief Financial OfficerSale600$13.51$8.1KForm 4
Aug 26, 2026Piscitelli DominicChief Financial OfficerSale77,000$13.69$1.1MForm 4
Jul 24, 2026Heyman Richard A.DirectorSale13,100$12.02$157.5KForm 4
Jul 6, 2026Heyman Richard A.DirectorSale300$12.00$3.6KForm 4
Feb 24, 2026Piscitelli DominicChief Financial OfficerSale52,000$13.51$702.5KForm 4
Jan 16, 2026Heyman Richard A.DirectorSale6,700$12.00$80.4KForm 4
Dec 16, 2025Piscitelli DominicChief Financial OfficerSale10,720$9.06$97.1KForm 4
Dec 16, 2025Chacko JacobPRESIDENT AND CEOSale33,374$9.06$302.4KForm 4
Dec 16, 2025Multani Pratik SChief Medical OfficerSale10,720$9.06$97.1KForm 4
Oct 6, 2025Piscitelli DominicChief Financial OfficerSale11,000$14.52$159.7KForm 4
Oct 6, 2025Chacko JacobPRESIDENT AND CEOSale37,461$12.32$461.5KForm 4
Oct 1, 2025Chacko JacobPRESIDENT AND CEOSale53,001$12.05$638.7KForm 4
Sep 30, 2025Chacko JacobPRESIDENT AND CEOSale34,538$12.01$414.8KForm 4
Sep 22, 2025Chacko JacobPRESIDENT AND CEOSale125,000$10.80$1.4MForm 4
Jul 1, 2025Piscitelli DominicChief Financial OfficerSale20,000$10.05$201.0KForm 4
Jun 24, 2025Piscitelli DominicChief Financial OfficerSale32,466$10.50$340.9KForm 4
Jun 23, 2025Piscitelli DominicChief Financial OfficerSale1,034$10.00$10.3KForm 4
Jun 23, 2025You AngieDirectorBuy1,403$9.43$13.2KForm 4
Jun 20, 2025You AngieDirectorBuy26,597$9.39$249.7KForm 4

All 51 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 29, 2025Raised $125 million in a private offering of equity Form D: 15 investors so far Form D
  2. Jan 23, 2024Raised $125 million in a private offering of equity Form D: 10 investors so far Form D
  3. Jun 27, 2023Raised $85 million in a private offering of equity Form D: 12 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nextech Invest Ltd.7,162,637$77.6M3.7%No change
BlackRock, Inc.6,823,973$73.9M0.0%+839,421
EcoR1 Capital, LLC6,728,116$72.9M3.6%No change
Viking Global Investors LP5,126,762$55.5M0.2%−697,771
State Street Corp4,894,000$53.0M0.0%+1,191,804
SR One Capital Management, LP4,615,384$50.0M4.8%+100,455
Venrock Adviser, LLC4,319,765$46.8M1.4%No change
NEA Management Company, LLC4,118,621$44.6M2.8%No change
Vanguard Capital Management LLC3,951,169$42.8M0.0%+264,162
AIHC Capital Management Ltd3,828,460$41.5M39.8%+1,368,909
Alkeon Capital Management LLC3,739,096$40.5M0.2%−765,000
Column Group LLC3,540,777$38.3M43.5%No change
Siren, L.L.C.2,998,192$32.5M0.7%No change
Fmr LLC2,635,475$28.5M0.0%+201,395
Citadel Advisors LLC2,595,299$28.1M0.0%+172,558
Goldman Sachs Group Inc2,451,796$26.6M0.0%+976,084
Geode Capital Management, LLC2,090,089$22.6M0.0%+251,288
First Turn Management, LLC2,017,284$21.8M2.3%No change
Orbimed Advisors LLC2,015,000$21.8M0.4%−678,929
Integral Health Asset Management, LLC1,900,000$20.6M0.8%+500,000
Mpm Bioimpact LLC1,882,162$20.4M1.2%+78,217
Vivo Capital, LLC1,848,786$20.0M1.8%No change
Dimensional Fund Advisors LP1,801,399$19.5M0.0%+330,109
Franklin Resources Inc1,797,377$19.5M0.0%+344,542
Morgan Stanley1,794,020$19.4M0.0%+111,497

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40